期刊文献+

间断或减量应用格列卫治疗胃肠间质瘤对疗效的影响分析 被引量:1

The Clinic Effect of Interrupting or Reducing the Use of Glivec on Gastrointestinal Stromal Tumor
下载PDF
导出
摘要 目的:探讨格列卫治疗胃肠间质瘤的疗效与其剂量及疗程的关系。方法:在用格列卫400mg/d治疗GIST取得疗效后,减量或停用,观察疗效变化。结果:停药或减量后病情复发、加重,再次服药或加量服药后1例患者无效,另1例再次有效。结论:格列卫治疗胃肠间质瘤取得疗效后,应按有效剂量持续服用,停药或减量服用应慎重,以免引起疗效下降。  Objective:To explore the relationship between the dose,therapeutic course and clinic effect of Glivec used for treatment of gastrointestinal stromal tumer(GIST).Methods:The change was observed by reducing the dose or stopping taking Glivec after getting effect at the dose of 400mg per day.Results:The patients' conditions were worsened or recured after reducing the dose of Glivec or stopping medication.After resumption of Glivec or increase of the dose the good result was shown in one case,but there was no improvement in another case.Conclution:Patients should keep on taking Glivec at effective dose after getting clinic effect.The medication should not be stopped,and the dose should not be decreased,so as not to cut down the effect.
出处 《医学理论与实践》 2007年第11期1250-1252,共3页 The Journal of Medical Theory and Practice
关键词 格列卫 胃肠间质瘤 疗效影响 Glivec,GIST,Influence of effect
  • 相关文献

参考文献4

  • 1Mazur MT, Clark HB. Gastricstromal tumors. Reappraisal of histogenesis [J]. Am J Sur Patholl,1983,7: 507-519.
  • 2Miettinen M, JY Blay, LH Sobin. Mesenchymal tumors of the stomach. WHO classification of tumours. Pathology and genetics of tumours of digestive system[M]. Lyon: IARC Press, 2000. 62-65.
  • 3Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract [J]. Histol Histopathol, 2000,15:1293-1301.
  • 4Heinrich MC,Corless CL, Duensing A, et al. PDGFRA activation mutations in gastrointestinal stromal tumors (abastract)[J]. Science, 2003,299 : 708-710.

同被引文献10

  • 1徐惠明,许春芳.胃肠道间质瘤的临床特征及免疫组化分析[J].苏州大学学报(医学版),2005,25(4):641-643. 被引量:2
  • 2Nunobe S,Sano T,Shimada K,et al.Surgery including liver resection for metastatic gastrointestinal stromal tumorsor gastrointestinal leiomyosarcomas[J].Jpn J Clin Oncol,2005,35(6):338-341.
  • 3DeMatteo RP,Shah A,Fong Y,et al.Results of hepatic resection for sarcoma metastatic to liver[J].Ann Surg,2001,234(4):540-548.
  • 4Rajan DK,Soulen MC,Clark TW,et al.Sarcomas metastastic to the liver:,response and survival after cisplatin,doxombicin,mitomycin-C,Ethiodol,and polyvinyl alcohol chemoembolization[J].J Vase Interv Radiol,2001,12(2):187-193.
  • 5Maluccio MA,Covey AM,Schubert J,et al.Treatment of metastatic sarcoma to the liver with bland embolization.Cancer[J].2006,107(7):1617-1623.
  • 6Hughes B,Yip D,Goldstein D,et al.Cerebral relapse of metastatic gastrointestinal stromal tumour during treatment with imatinib mesylate:case report[J].BMC Cancer,2004,4:74-80.
  • 7D'Amato G,Steinert DM,MeAuliffe JC,et al.Update on the biology and therapy of gastrointestinal stromal minors[J].Cancer Control,2005,12(1):44-56.
  • 8Joensuu H,De Braud F,Coco P,et al.Phase IL open-lahel study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate[J].Annals of Oneology,2008,19(1):173-177.
  • 9秦新裕,刘凤林.胃肠道间质瘤的研究进展与展望[J].中华普通外科杂志,2007,22(8):561-563. 被引量:34
  • 10牛洪欣,何庆泗.胃肠道间质瘤现代研究进展[J].中国普通外科杂志,2007,16(9):895-897. 被引量:20

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部